难治性精神分裂症的心理与社会心理干预:系统综述与网络荟萃分析
该系统综述与网络荟萃分析纳入52项随机对照试验共5034例难治性精神分裂症患者,比较20种心理与社会心理干预。认知行为疗法用于精神病(CBTp)在减轻总体症状上优于标准治疗(SMD -0.22,95%CI -0.35至-0.09),虚拟现实干预、整合干预和音乐疗法也显示优于标准治疗;其他干预有希望但需进一步研究。
要点
- CBTp优于标准治疗减轻难治性精神分裂症总体症状(SMD -0.22,95%CI -0.35至-0.09,35项试验)。
- 虚拟现实干预、整合干预和音乐疗法也优于标准治疗,但证据质量不一。
- 作者认为临床医生可优先采用CBTp,其他干预需进一步研究。
核心结论
- CBTp可减轻难治性精神分裂症患者的总体症状,临床医生可优先采用该干预。
- 其他心理与社会心理干预显示出有希望的结果,但需要进一步研究。
研究设计与样本
- 系统综述与网络荟萃分析,检索BIOSIS、CINAHL、Embase、LILACS、MEDLINE、PsychInfo、ClinicalTrials.gov、WHO国际临床试验注册平台(建库至2020年1月31日)、Cochrane精神分裂症组注册库(建库至2022年3月31日)及PubMed和Cochrane CENTRAL(建库至2023年7月31日)。
- 纳入难治性精神分裂症患者的随机对照试验,主要结局为总体症状。
- 52项随机对照试验共5034例参与者(女性1654例[33.2%],男性3325例[66.8%],性别已注明)纳入网络荟萃分析,比较20种心理与社会心理干预;参与者平均年龄38.05岁(范围23.10-48.50)。
- 采用随机效应配对荟萃分析和网络荟萃分析计算标准化均数差或风险比及95%CI。
- 研究方案注册于PROSPERO,CRD42022358696;研究过程中无有生活经验者参与。
主要发现
- CBTp优于标准治疗减轻总体症状(SMD -0.22,95%CI -0.35至-0.09,35项试验)。
- 虚拟现实干预优于标准治疗减轻总体症状(SMD -0.41,95%CI -0.79至-0.02,4项试验)。
- 整合干预优于标准治疗减轻总体症状(SMD -0.70,95%CI -1.18至-0.22,3项试验)。
- 音乐疗法优于标准治疗减轻总体症状(SMD -1.27,95%CI -1.83至-0.70,1项研究)。
- 未发现发表偏倚迹象。
关键数值与推荐
- CBTp:SMD -0.22(95%CI -0.35至-0.09),35项试验,优于标准治疗。
- 虚拟现实干预:SMD -0.41(95%CI -0.79至-0.02),4项试验,优于标准治疗。
- 整合干预:SMD -0.70(95%CI -1.18至-0.22),3项试验,优于标准治疗。
- 音乐疗法:SMD -1.27(95%CI -1.83至-0.70),1项研究,优于标准治疗。
临床怎么用
- 作者认为临床医生可在临床实践中优先采用CBTp。
- 其他心理与社会心理干预显示出有希望的结果,但需要进一步研究。
局限性
- 研究旨在收集种族数据,但报告极少。
- 其他心理与社会心理干预显示出有希望的结果,但需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many patients with schizophrenia have symptoms that do not respond to antipsychotics. This condition is called treatment-resistant schizophrenia and has not received specific attention as opposed to general schizophrenia. Psychological and psychosocial interventions as an add-on treatment to pharmacotherapy could be useful, but their role and comparative efficacy to each other and to standard care in this population are not known. We investigated the efficacy, acceptability, and tolerability of psychological and psychosocial interventions for patients with treatment-resistant schizophrenia. METHODS: In this systematic review and network meta-analysis (NMA), we searched for published and unpublished randomised controlled trials (RCTs) through a systematic database search in BIOSIS, CINAHL, Embase, LILACS, MEDLINE, PsychInfo, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform for articles published from inception up to Jan 31, 2020. We also searched the Cochrane Schizophrenia Group registry for studies published from inception up to March 31, 2022, and PubMed and Cochrane CENTRAL for studies published from inception up to July 31, 2023. We included RCTs that included patients with treatment-resistant schizophrenia. The primary outcome was overall symptoms. We did random-effects pairwise meta-analyses and NMAs to calculate standardised mean differences (SMDs) or risk ratios with 95% CIs. No people with lived experience were involved throughout the research process. The study protocol was registered in PROSPERO, CRD42022358696. FINDINGS: We identified 30 326 records, excluding 24 526 by title and abstract screening. 5762 full-text articles were assessed for eligibility, of which 5540 were excluded for not meeting the eligibility criteria, and 222 reports corresponding to 60 studies were included in the qualitative synthesis. Of these, 52 RCTs with 5034 participants (1654 [33·2%] females and 3325 [66·8%] males with sex indicated) comparing 20 psychological and psychosocial interventions provided data for the NMA. Mean age of participants was 38·05 years (range 23·10-48·50). We aimed to collect ethnicity data, but they were scarcely reported. According to the quality of evidence, cognitive behavioural therapy for psychosis (CBTp; SMD -0·22, 95% CI -0·35 to -0·09, 35 trials), virtual reality intervention (SMD -0·41, -0·79 to -0·02, four trials), integrated intervention (SMD -0·70, -1·18 to -0·22, three trials), and music therapy (SMD -1·27, -1·83 to -0·70, one study) were more efficacious than standard care in reducing overall symptoms. No indication of publication bias was identified. INTERPRETATION: We provide robust findings that CBTp can reduce the overall symptoms of patients with treatment-resistant schizophrenia, and therefore clinicians can prioritise this intervention in their clinical practice. Other psychological and psychosocial interventions showed promising results but need further investigation. FUNDING: DAAD-ASFE.
引用
- Salahuddin NH, Schütz A, Pitschel-Walz G, et al. Psychological and psychosocial interventions for treatment-resistant schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry. 2024. PMID: 38879276. doi:10.1016/S2215-0366(24)00136-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。